MARKET

ATHA

ATHA

Athira Pharma, Inc.
NASDAQ
7.68
+3.55
+85.73%
Opening 10:24 12/18 EST
OPEN
7.22
PREV CLOSE
4.135
HIGH
8.35
LOW
7.15
VOLUME
45.36M
TURNOVER
--
52 WEEK HIGH
8.35
52 WEEK LOW
2.195
MARKET CAP
30.29M
P/E (TTM)
-0.7937
1D
5D
1M
3M
1Y
5Y
1D
Dow Surges 400 Points; Accenture Earnings Top Views
Benzinga · 38m ago
Athira Soars On Securing Exclusive Rights To Breast Cancer Drug Candidate Lasofoxifene
NASDAQ · 50m ago
Why Is Athira Pharma Stock (ATHA) Up Today?
TipRanks · 2h ago
Athira Pharma pivots to oncology with new licensing deal
TipRanks · 2h ago
Market-Moving News for December 18th
Benzinga · 3h ago
Athira Pharma announces license to develop, commercialize lasofoxifene
TipRanks · 3h ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 3h ago
Athira Pharma To Acquire Rights For Development And Commercialization Of Lasofoxifene, A Clinical Asset In Potentially Registrational Phase 3 Trial
Benzinga · 3h ago
More
About ATHA
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. It has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.

Webull offers Athira Pharma Inc stock information, including NASDAQ: ATHA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATHA stock methods without spending real money on the virtual paper trading platform.